Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 20/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.81 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.81 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.81 |
| ▸ | F2 | P00734 | 1/20 | 0.63 |
| ▸ | F11 | P03951 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21145619 | 0.90 | KLKB1 (0.82) | KLKB1CYP3A4CYP2C8CYP2C9F2 | |
| SCHEMBL17785386 | 0.90 | KLKB1 (0.81) | KLKB1CYP3A4CYP2C8CYP2C9F2 | |
| SCHEMBL17785373 | 0.90 | KLKB1 (1.00) | KLKB1CYP3A4CYP2C8CYP2C9F2 | |
| SCHEMBL21145552 | 0.89 | KLKB1 (0.82) | KLKB1CYP3A4CYP2C8CYP2C9F2 | |
| SCHEMBL17785319 | 0.88 | KLKB1 (1.00) | KLKB1 | |
| SCHEMBL21145561 | 0.87 | KLKB1 (0.83) | KLKB1CYP3A4CYP2C8CYP2C9F2 | |
| SCHEMBL21145545 | 0.86 | KLKB1 (1.00) | KLKB1CYP3A4CYP2C8CYP2C9 | |
| SCHEMBL24863390 | 0.86 | KLKB1 (0.76) | KLKB1CYP3A4CYP2C8CYP2C9F2 | |
| SCHEMBL24863726 | 0.86 | KLKB1 (0.75) | KLKB1CYP3A4CYP2C8CYP2C9F2 | |
| SCHEMBL25659764 | 0.86 | KLKB1 (0.75) | KLKB1CYP3A4CYP2C8CYP2C9F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220002275-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LTD (GB) | 2022-01-06 | — | — | US | claimed |
| CN-113387933-A | Pyrazole derivatives as plasma kallikrein inhibitors | 卡尔维斯塔制药有限公司 | 2021-09-14 | — | — | CN | claimed |
| EP-3760622-A1 | PYRAZOLE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | Kalvista Pharmaceuticals Limited (GB) | 2021-01-06 | — | — | EP | claimed |
| US-20250074903-A1 | N-((HET)Arylmethyl)-Heteroaryl-Carboxamides Compounds As Kallikrein Inhibitors | DRI UK LP (KY) | 2025-03-06 | — | — | US | disclosed |
| US-20220289729-A1 | N-((HET)Arylmethyl)-Heteroaryl-Carboxamides Compounds As Kallikrein Inhibitors | KALVISTA PHARMACEUTICALS LTD (GB) | 2022-09-15 | — | — | US | disclosed |
| EP-4039681-A1 | N-((HET)ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS | Kalvista Pharmaceuticals Limited (GB) | 2022-08-10 | — | — | EP | disclosed |
| US-20220002275-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LTD (GB) | 2022-01-06 | — | — | US | disclosed |
| EP-3556752-B1 | N-((HET)ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS | KALVISTA PHARMACEUTICALS LTD (GB) | 2022-01-05 | — | — | EP | disclosed |
| US-11198691-B2 | N-((het)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-12-14 | — | — | US | disclosed |
| US-11180484-B2 | Pyrazole derivatives as plasma kallikrein inhibitors | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-11-23 | — | — | US | disclosed |
| CN-113387933-A | Pyrazole derivatives as plasma kallikrein inhibitors | 卡尔维斯塔制药有限公司 | 2021-09-14 | — | — | CN | disclosed |
| US-20190330200-A1 | N-((HET)ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS KALLIKREIN INHIBITORS | DRI UK LP (KY) | 2019-10-31 | — | — | US | disclosed |
| EP-3556752-A1 | N-((HET)ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS | Kalvista Pharmaceuticals Limited (GB) | 2019-10-23 | — | — | EP | disclosed |
| US-20190300517-A1 | N-((HET)Arylmethyl)-Heteroaryl-Carboxamides Compounds As Plasma Kallikrein Inhibitors | DRI UK LP (KY) | 2019-10-03 | — | — | US | disclosed |
| US-10364238-B2 | N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2019-07-30 | — | — | US | disclosed |
| US-20190218205-A1 | PYRAZOLE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2019-07-18 | — | — | US | disclosed |
| EP-3224256-B1 | N-((HET)ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS, | KALVISTA PHARMACEUTICALS LTD (GB) | 2019-07-03 | — | — | EP | disclosed |
| US-20180319782-A1 | N-((HET) ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS | DRI UK LP (KY) | 2018-11-08 | — | — | US | disclosed |
| EP-3224256-A1 | N-((HET)ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS, | Kalvista Pharmaceuticals Limited (GB) | 2017-10-04 | — | — | EP | disclosed |
| WO-2016083820-A1 | N-((HET)ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS, | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2016-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180319782-A1 | N-((HET) ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS | KLKB1, BDKRB1, BDKRB2 | KLKB1 1/4885CYP3A4 1216/4885CYP2C8 980/4885 |
| US-11180484-B2 | Pyrazole derivatives as plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | KLKB1 1/4885CYP3A4 551/4885CYP2C8 1329/4885 |
| US-20220002275-A1 | ENZYME INHIBITORS | SERPINB1, KLKB1, SERPINE1 | KLKB1 2/4885CYP3A4 1365/4885CYP2C8 2310/4885 |
| US-20190218205-A1 | PYRAZOLE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | KLKB1 1/4885CYP3A4 551/4885CYP2C8 1329/4885 |
| US-10364238-B2 | N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors | KLKB1, BDKRB1, BDKRB2 | KLKB1 1/4885CYP3A4 1216/4885CYP2C8 980/4885 |
| US-20220289729-A1 | N-((HET)Arylmethyl)-Heteroaryl-Carboxamides Compounds As Kallikrein Inhibitors | KLKB1, BDKRB1, BDKRB2 | KLKB1 1/4885CYP3A4 1261/4885CYP2C8 1116/4885 |
| US-11198691-B2 | N-((het)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors | KLKB1, BDKRB1, BDKRB2 | KLKB1 1/4885CYP3A4 1261/4885CYP2C8 1116/4885 |
| US-20190300517-A1 | N-((HET)Arylmethyl)-Heteroaryl-Carboxamides Compounds As Plasma Kallikrein Inhibitors | KLKB1, BDKRB1, BDKRB2 | KLKB1 1/4885CYP3A4 1231/4885CYP2C8 1099/4885 |
| US-20190330200-A1 | N-((HET)ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS KALLIKREIN INHIBITORS | KLKB1, BDKRB1, BDKRB2 | KLKB1 1/4885CYP3A4 1261/4885CYP2C8 1116/4885 |
| US-20250074903-A1 | N-((HET)Arylmethyl)-Heteroaryl-Carboxamides Compounds As Kallikrein Inhibitors | KLKB1, BDKRB1, BDKRB2 | KLKB1 1/4885CYP3A4 1261/4885CYP2C8 1116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.